StockIQ.techCapricor Therapeutics, Inc. (CAPR) Stock Analysis
Free AI-powered analysis and research for Capricor Therapeutics, Inc. stock
Sector: Healthcare
Full CAPR report
Capricor Therapeutics, Inc. (CAPR) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze CAPR Now →📰 Latest Update
CAPR Stock Rallies Into FDA Decision Month: Retail Spots Approval ‘Tea Leaves’ In Capricor’s Launch Team Hiring
Mon, November 2, 2026 at 4:21 AM UTC 3 min read
Capricor Therapeutics (CAPR) shares rose over 4% as retail investors speculated that recent job postings for launch-related positions indicated an impending FDA approval for its Duchenne muscular dystrophy treatment, Deramiocel. Despite a significant 33% decline in October, the company is preparing for a potential U.S. launch, with roles focused on commercial operations and patient services. The FDA's decision deadline for Deramiocel is set for November 22, following a delay from August.